Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
- Pevonedistat Granted FDA’s Breakthrough Therapy Status for Higher-Risk MDS: Takeda
August 3, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
- Kyowa Kirin’s 1H Sales Up 4.2% Driven by Overseas Biz; Full-Year Guidance Down on Slack Nesp AG, COVID-19
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Teva Takeda Deal Aimed at Boosting Efficiency, Quality: Nichi-Iko Chief
July 31, 2020
- Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
- Nichi-Iko Pulls Out from Avigan Contract Manufacturing
July 31, 2020
- 28 Products from 10-Plus Firms Recalled due to Flawed Tests at Kyowa CritiCare
July 31, 2020
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Eisai Seeks Lenvima’s Label Expansion into Thymic Carcinoma
July 31, 2020
- Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
- Healios Starts Enrolling COVID-19 Patients in ARDS Cell Therapy Program
July 30, 2020
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Otsuka Files Japan NDA for Preventive Treatment of Migraines
July 30, 2020
- Generic APIs at Crossroads - 1: Sawai Quality Chief Says Current Biz Structure Hampers Manufacturing Repatriation
July 29, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…